The IL-36γ-mediated anti-tumorigenic response was characterised by a reduction in tumour-promoting B cells, a reduction in Gr1+ neutrophilic myeloid-derived suppressor cells (MDSCs) and enhanced expression of MHC class II molecules across all MDSC subsets. This evidence concerns the gene IL36G and neoplasm.